Bruce E. Sands, MD, MS, FACG

Icahn School of Medicine at Mount Sinai

Poster(s):

• P2200 - Efficacy and Safety of Etrasimod in Patients With and Without Concomitant Corticosteroid Treatment in the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials
  Monday, October 23, 2023

  10:30 AM – 4:15 PM PT

• P2201 - Effect of 104 Weeks of Mirikizumab Treatment on Inflammatory Bowel Disease Questionnaire Scores Among Patients With Moderately to Severely Active Crohn’s Disease
  Monday, October 23, 2023

  10:30 AM – 4:15 PM PT

• P2202 - Improvement in Inflammatory Biomarker Levels Through Week 12 in Moderately to Severely Active Ulcerative Colitis Patients Treated With Guselkumab: Results From the Phase 3 QUASAR Induction Study
  Monday, October 23, 2023

  10:30 AM – 4:15 PM PT

• P2203 - Association Between Efficacy and Long-Term Outcomes: Four Year Results From the UNIFI Study of Ustekinumab in Ulcerative Colitis
  Monday, October 23, 2023

  10:30 AM – 4:15 PM PT

• P2204 - Endoscopic and Histologic Remission After 2 Years Treatment With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis
  Monday, October 23, 2023

  10:30 AM – 4:15 PM PT

• P2205 - Sustained Improvement in Inflammatory Bowel Disease Questionnaire Outcomes in Moderately to Severely Active Ulcerative Colitis with Continued Mirikizumab Treatment in Phase 3 LUCENT-3 Study
  Monday, October 23, 2023

  10:30 AM – 4:15 PM PT

• P2206 - Impact of Prior Biologic/Janus Kinase Inhibitor Therapy on the Efficacy of Etrasimod: Subgroup Analysis From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials
  Monday, October 23, 2023

  10:30 AM – 4:15 PM PT